Eva Markert

552 total citations
20 papers, 405 citations indexed

About

Eva Markert is a scholar working on Pulmonary and Respiratory Medicine, Rheumatology and Oncology. According to data from OpenAlex, Eva Markert has authored 20 papers receiving a total of 405 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 10 papers in Rheumatology and 7 papers in Oncology. Recurrent topics in Eva Markert's work include Rheumatoid Arthritis Research and Therapies (5 papers), Sarcoma Diagnosis and Treatment (4 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). Eva Markert is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (5 papers), Sarcoma Diagnosis and Treatment (4 papers) and Radiopharmaceutical Chemistry and Applications (2 papers). Eva Markert collaborates with scholars based in Germany, Switzerland and United States. Eva Markert's co-authors include Omar Hasan Ali, Lukas Flatz, Stefan Diem, Lars E. French, Katrin Kerl, Wolfram Jochum, Martin Früh, Daniel E. Speiser, Roman K. Thomas and Burkhard Möller and has published in prestigious journals such as PLoS ONE, The American Journal of Surgical Pathology and Journal of Vascular Surgery.

In The Last Decade

Eva Markert

17 papers receiving 397 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eva Markert Germany 9 181 167 129 82 63 20 405
Hiroyuki Yamaoka Japan 13 146 0.8× 103 0.6× 86 0.7× 69 0.8× 42 0.7× 37 471
James B. Hayden United States 10 177 1.0× 265 1.6× 117 0.9× 76 0.9× 58 0.9× 30 487
Camille Schiffler France 10 152 0.8× 251 1.5× 59 0.5× 87 1.1× 34 0.5× 24 385
Laura Yébenes Spain 11 134 0.7× 93 0.6× 48 0.4× 72 0.9× 32 0.5× 24 347
Wolfgang Beck United States 3 139 0.8× 229 1.4× 112 0.9× 72 0.9× 45 0.7× 5 336
Marie‐Pierre Castex France 11 81 0.4× 212 1.3× 70 0.5× 100 1.2× 21 0.3× 23 362
Mihaela Druta United States 14 252 1.4× 255 1.5× 63 0.5× 63 0.8× 72 1.1× 43 437
Kumaran Mudaliar United States 11 117 0.6× 335 2.0× 77 0.6× 168 2.0× 39 0.6× 37 531
Jake Allred United States 8 258 1.4× 57 0.3× 57 0.4× 55 0.7× 32 0.5× 13 373
Olga L. Bohn United States 11 141 0.8× 81 0.5× 59 0.5× 77 0.9× 39 0.6× 18 352

Countries citing papers authored by Eva Markert

Since Specialization
Citations

This map shows the geographic impact of Eva Markert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Markert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Markert more than expected).

Fields of papers citing papers by Eva Markert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Markert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Markert. The network helps show where Eva Markert may publish in the future.

Co-authorship network of co-authors of Eva Markert

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Markert. A scholar is included among the top collaborators of Eva Markert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Markert. Eva Markert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jones, Douglas W., Jessica P. Simons, Eva Markert, et al.. (2025). Earned outcome metrics outperform recommended open abdominal aortic aneurysm repair volume guidelines in discriminating perioperative mortality among centers. Journal of Vascular Surgery. 82(6). 2036–2045.e2.
2.
Markert, Eva, et al.. (2023). Pitfalls in correct diagnosis and treatment of Soft Tissue Sarcoma of the foot and ankle – A report of two challenging cases. Fuß & Sprunggelenk. 21(1). 55–69. 1 indexed citations
3.
Markert, Eva, et al.. (2023). Spindle cell/pleomorphic lipoma of the seminal vesicle: First description of a rare benign mesenchymal tumor. Urology Case Reports. 47. 102337–102337.
4.
Haberecker, Martina, Marco M. Bühler, Roman Guggenberger, et al.. (2022). Molecular and immunophenotypic characterization of SMARCB1 (INI1) - deficient intrathoracic Neoplasms. Modern Pathology. 35(12). 1860–1869. 8 indexed citations
5.
Ali, Omar Hasan, Fiamma Berner, Christoph Ackermann, et al.. (2020). Fingolimod and tumor-infiltrating lymphocytes in checkpoint-inhibitor treated cancer patients. Cancer Immunology Immunotherapy. 70(2). 563–568. 6 indexed citations
6.
Amary, Fernanda, Eva Markert, Fitim Berisha, et al.. (2019). FOS Expression in Osteoid Osteoma and Osteoblastoma. The American Journal of Surgical Pathology. 43(12). 1661–1667. 46 indexed citations
7.
Ali, Omar Hasan, Stefan Diem, Eva Markert, et al.. (2016). Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. OncoImmunology. 5(11). e1231292–e1231292. 99 indexed citations
8.
Querings, Silvia, Janine Altmüller, Sascha Ansén, et al.. (2011). Benchmarking of Mutation Diagnostics in Clinical Lung Cancer Specimens. PLoS ONE. 6(5). e19601–e19601. 97 indexed citations
9.
Ansén, Sascha, Christopher Bangard, Silvia Querings, et al.. (2010). Osteoblastic Response in Patients with Non-small Cell Lung Cancer with Activating EGFR Mutations and Bone Metastases during Treatment with EGFR Kinase Inhibitors. Journal of Thoracic Oncology. 5(3). 407–409. 12 indexed citations
10.
Ohlmann, Carsten‐Henning, Eva Markert, Hans‐Peter Dienes, et al.. (2009). Improving the efficacy of targeted trials by multiple-marker analysis in castration-resistant prostate cancer. Urologic Oncology Seminars and Original Investigations. 29(6). 664–669. 4 indexed citations
11.
Markert, Eva, Udo Siebolts, Margarete Odenthal, Karl‐Anton Kreuzer, & Claudia Wickenhauser. (2009). High diagnostic value of morphologic examination and molecular analysis of bone marrow biopsies in a case of BCR-ABL+ CML with clusters of blasts. International Journal of Hematology. 89(3). 294–297. 2 indexed citations
12.
Ohlmann, Carsten‐Henning, Eva Markert, David Pfister, et al.. (2008). Molekular getriggerte Therapie des hormonrefraktären Prostatakarzinoms. Der Urologe. 47(9). 1218–1223.
13.
Vent, Julia, Gero Quante, Eva Markert, Jens Peter Klußmann, & Dirk Beutner. (2008). Zervikales Neurofibrom als Ursache von Globusgefühl. HNO. 57(6). 625–628. 2 indexed citations
14.
Markert, Eva, et al.. (2006). Lung osteoma—a new benign lung lesion. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 449(1). 117–120. 2 indexed citations
15.
Maercker, Christian, et al.. (2006). Enhanced proliferation and decreased apoptosis in lung lavage cells of sarcoidosis patients.. PubMed. 23(3). 190–200. 5 indexed citations
16.
Seidl, Christian, Ute Koch, Burkhard Möller, et al.. (1999). Association of (Q)R/KRAA positive HLA-DRB1 alleles with disease progression in early active and severe rheumatoid arthritis.. PubMed. 26(4). 773–6. 14 indexed citations
17.
Zeidler, H., T.K. Kvien, Pekka Hannonen, et al.. (1998). Progression of joint damage in early active severe rheumatoid arthritis during 18 months of treatment: comparison of low-dose cyclosporin and parenteral gold. Lara D. Veeken. 37(8). 874–882. 51 indexed citations
18.
Seidl, Christian, Ute Koch, R. Frank, et al.. (1997). HLA‐DR/DQ/DP INTERACTIONS IN RHEUMATOID ARTHRITIS. European Journal of Immunogenetics. 24(5). 365–376. 16 indexed citations
19.
Seidl, Christian, Ute Koch, Burkhard Möller, et al.. (1997). HLA-DRB1*04 subtypes are associated with increased inflammatory activity in early rheumatoid arthritis. Lara D. Veeken. 36(9). 941–944. 26 indexed citations
20.
Kovarik, John M., Pekka Kurki, E. Mueller, et al.. (1996). Diclofenac combined with cyclosporine in treatment refractory rheumatoid arthritis: longitudinal safety assessment and evidence of a pharmacokinetic/dynamic interaction.. PubMed. 23(12). 2033–8. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hiroyuki Yamaoka Breakdown of academic impact, for papers by James B. Hayden Breakdown of academic impact, for papers by Camille Schiffler Breakdown of academic impact, for papers by Laura Yébenes Breakdown of academic impact, for papers by Wolfgang Beck Breakdown of academic impact, for papers by Marie‐Pierre Castex Breakdown of academic impact, for papers by Mihaela Druta Breakdown of academic impact, for papers by Kumaran Mudaliar Breakdown of academic impact, for papers by Jake Allred Breakdown of academic impact, for papers by Olga L. Bohn
Rankless by CCL
2026